El Salvador vs Namibia: Average cost of tuberculosis treatment by type
El Salvador
14 constant 2022 US$
in 2024
Namibia
13 constant 2022 US$
in 2024
El Salvador rank
40th
Namibia rank
42nd
Average cost of tuberculosis treatment by type over time
- El Salvador
- Namibia
How they compare
El Salvador currently reports 14 constant 2022 US$ against 13 constant 2022 US$ in Namibia, a difference of 1 constant 2022 US$.
That makes El Salvador's figure about 1.1 times Namibia's.
The two have swapped places 1 time across 6 shared years of data; in 2019 it was Namibia ahead.
El Salvador ranks 40th and Namibia ranks 42nd of 62 countries.
El Salvador has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | El Salvador | Namibia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 7 constant 2022 US$ | 7 constant 2022 US$ | 0 constant 2022 US$ | — |
| 2020s | 65.4 constant 2022 US$ | 12.2 constant 2022 US$ | 53.2 constant 2022 US$ | El Salvador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of tuberculosis treatment by type, El Salvador or Namibia?
- El Salvador, at 14 constant 2022 US$ against 13 constant 2022 US$ in Namibia as of 2024.
- What is the difference in average cost of tuberculosis treatment by type between El Salvador and Namibia?
- 1 constant 2022 US$, with El Salvador ahead.
- How many years of comparable data are there for El Salvador and Namibia?
- 6 years are reported by both, from 2019 to 2024.
- How do El Salvador and Namibia rank globally for average cost of tuberculosis treatment by type?
- El Salvador ranks 40th and Namibia ranks 42nd of 62 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of tuberculosis treatment by type. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per person starting tuberculosis preventive treatment, excluding buffer stock.